mcc-555 has been researched along with Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eckel, J; Ishii, S; Liu, LS; Tanaka, H | 1 |
| Ishii, S; Tanaka, H; Upton, R; Widdowson, PS; Williams, G | 1 |
2 other study(ies) available for mcc-555 and Obesity
| Article | Year |
|---|---|
The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes.
Topics: Animals; Blotting, Western; Glucose; Heart; Hypoglycemic Agents; Insulin; Male; Myocardium; Obesity; Phosphatidylinositol 3-Kinases; Precipitin Tests; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Rats, Zucker; Signal Transduction; Thiazoles; Thiazolidinediones | 1998 |
Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Topics: Animals; Basal Metabolism; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Fatty Acids; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver Glycogen; Male; Obesity; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Treatment Outcome; Triglycerides | 1998 |